Table 3.
Univariable and multivariable Cox regression analysis of basic demographics, clinical composite scores and pathophysiological data.
| Univariable Model | Multivariable Model | |||||||
|---|---|---|---|---|---|---|---|---|
| HR | p | Lower | Upper | HR | p | 95% CI | ||
| Cause Specific Survival | ||||||||
| Sex (Male) | 3.65 | 0.026 | 1.16 | 11.4 | ||||
| Age years (<56 vs. >56) | 1.55 | 0.398 | 0.56 | 4.28 | ||||
| Histology (TC vs. Thymoma) | 11.1 | 0.001 | 3.43 | 34.4 | 26.0 | 0.001 | 4.50 | 151.3 |
| Resection Status (R1–2 vs. R0) | 3.70 | 0.025 | 1.17 | 11.7 | 13.5 | 0.018 | 1.56 | 117.4 |
| Myasthenia Gravis (No) | 5.65 | 0.094 | 0.74 | 43.0 | ||||
| Tumor Stage* (III–IV vs. I + II) | 5.52 | 0.003 | 1.75 | 17.3 | 2.21 | 0.407 | 0.33 | 14.59 |
| ASA (III–IV vs. I + II) | 0.98 | 0.983 | 0.31 | 3.06 | ||||
| ALI (low vs. high) | 3.47 | 0.049 | 1.00 | 12.0 | 2.43 | 0.321 | 0.42 | 14.08 |
| CFS (1 vs. 0) | 5.94 | 0.002 | 1.88 | 18.7 | 1.60 | 0.539 | 0.356 | 7.22 |
| GPS (2 vs. 0 + 1) | 4.90 | 0.040 | 1.07 | 22.3 | ||||
| TET-aGPS (1 vs. 0) | 5.18 | 0.014 | 1.40 | 19.1 | 14.9 | 0.017 | 1.63 | 137.4 |
| HS-mGPS (2 + 1 vs. 0) | 4.87 | 0.041 | 1.06 | 22.2 | ||||
| SII (high vs. low) | 4.28 | 0.066 | 0.01 | 20.1 | ||||
| Freedom From Recurrence | ||||||||
| Sex (Male) | 2.37 | 0.022 | 1.13 | 4.94 | ||||
| Age years (<50 vs. >50) | 1.92 | 0.070 | 0.94 | 3.88 | ||||
| Histology (TC vs. Thymoma) | 4.45 | 0.001 | 2.19 | 9.04 | 28.2 | 0.001 | 6.22 | 128.1 |
| Resection Status (R1–2 vs. R0) | 3.55 | 0.003 | 1.53 | 8.26 | 13.9 | 0.003 | 2.52 | 77.29 |
| Myasthenia Gravis (No) | 3.77 | 0.029 | 1.14 | 12.4 | ||||
| Tumor Stage* (III–IV vs. I + II) | 4.86 | 0.001 | 2.37 | 10.5 | 4.78 | 0.042 | 1.06 | 21.59 |
| ASA (III–IV vs. I + II) | 1.05 | 0.906 | 0.43 | 2.54 | ||||
| ALI (low vs. high) | 2.92 | 0.038 | 1.06 | 8.07 | 2.89 | 0.119 | 0.76 | 11.04 |
| CFS (1 vs. 0) | 4.56 | 0.001 | 2.01 | 10.3 | 1.18 | 0.850 | 0.30 | 4.31 |
| GPS (2 vs. 0 + 1) | 5.13 | 0.009 | 1.50 | 17.5 | ||||
| TET-aGPS (2 + 1 vs. 0) | 3.17 | 0.009 | 1.33 | 7.57 | 3.44 | 0.093 | 0.81 | 14.57 |
| HS-mGPS (1 vs. 0) | 3.58 | 0.012 | 1.32 | 9.73 | ||||
| SII (high vs. low) | 2.65 | 0.066 | 0.93 | 7.55 | ||||
Multivariable cox regression for CSS and FFR was performed with all significant parameters (p < 0.05) of the univariable analysis for CSS, despite of sex. Only the most significant GPS score of the univariable analysis for CSS was included in the multivariable analysis of CSS and FFR.
ASA American Society of Anesthesiology classification of Physical Health, ALI advanced lung cancer inflammation index, CFS CRP/Fibrinogen Prognostic score, GPS Glasgow Prognostic Score, HS-mGPS the high-sensitivity modified Glasgow Prognostic Score, TET-aGPS thymic epithelial tumor adapted Glasgow Prognostic Score, SII systemic immune-inflammation index, w/o without, *Masaoka- Koga tumor stage.